Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 2 |
+8 more TTM periods Free account |
| (154.91%) | (129.15%) | (96.99%) | (66.93%) | ||
| (117.46%) | (104.27%) | (81.98%) | (58.31%) | ||
ROIC |
(141.24%) | (69.46%) | (56.24%) | (39.10%) | |
Return on Tangible Assets |
2,095.71% | 21,295.09% | (1,396.34%) | (455.03%) | |
Average Days of Receivables |
0.00 | 0.00 | 87.63 | 101.88 | |
Free Cash Flow per Share |
(2.88) | (2.97) | (2.93) | (1.98) | |
Free Cash Flow |
(2.95) | (2.93) | (2.62) | (1.86) | |
| Other line items | |||||
Cash ROIC |
(87.05%) | (54.42%) | (33.90%) | (18.28%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 4.82 | 0.74 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 804.27% | 358.40% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,773.02% | 1,009.07% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 84.82% | 43.70% | |
Interest Coverage |
694.32 | (3,705.67) | (180.70) | (148.15) | |
Operating CF/Net income |
0.34 | 0.34 | 0.32 | 0.27 | |
Depreciation/Fixed assets |
82.33 | 25.38 | 11.33 | 30.30 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.11 | 0.24 | |
Operating CF per Share |
(2.88) | (2.97) | (2.93) | (1.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026